title: Lateral rectus muscle paralysis induced by ribavirin and pegylated interferon-α2a in a patient with HIV/HCV co-infection.
abstract: We report a lateral rectus muscle paralysis occurring 2 weeks after initiation of an interferon-α and ribavirin treatment in a patient with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) virus co-infection. This patient presented with horizontal diplopia that appeared rapidly and without any other neurological symptoms. Symptoms fully resolved with treatment interruption without any ophthalmological sequelae. This side effect is rare and has never been reported in a HIV-HCV co-infected patient.
authors.affiliation: Infectious Diseases Department, La Pitié-Salpêtrière Hospital, 83 Boulevard de l'Hôpital, 75013 Paris, France. guillaume_mellon@yahoo.fr
authors.forename: Guillaume
authors.initials: G
authors.lastname: Mellon
authors.forename: Hind
authors.initials: H
authors.lastname: Stitou
authors.forename: Olivier
authors.initials: O
authors.lastname: Aoun
authors.forename: Roland
authors.initials: R
authors.lastname: Tubiana
authors.forename: Vincent
authors.initials: V
authors.lastname: Thibault
authors.forename: Marc Antoine
authors.initials: MA
authors.lastname: Valantin
authors.forename: François
authors.initials: F
authors.lastname: Bricaire
mesh_terms: D020434:Abducens Nerve Diseases / Q000139:chemically induced* / Q000175:diagnosis; D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005123:Eye / Q000187:drug effects / Q000503:physiopathology; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D018482:Muscle, Skeletal / Q000187:drug effects / Q000503:physiopathology; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012254:Ribavirin / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a